MARKET

PULM

PULM

Pulmatrix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.140
+0.100
+9.62%
After Hours: 1.110 -0.03 -2.63% 19:59 06/11 EDT
OPEN
1.050
PREV CLOSE
1.040
HIGH
1.170
LOW
1.050
VOLUME
1.73M
TURNOVER
--
52 WEEK HIGH
3.040
52 WEEK LOW
0.8200
MARKET CAP
64.12M
P/E (TTM)
-2.1575
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers
Benzinga · 06/02 20:37
BRIEF-Pulmatrix Inc Files For Mixed Shelf Of Upto $100 Million - SEC Filing
reuters.com · 05/26 22:52
Pulmatrix Posts Application For U.S. Patent Titled 'ANTIFUNGAL FORMULATIONS FOR PULMONARY ADMINISTRATION COMPRISING ITRACONAZOLE'
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220210145739%22.PGNR.&OS=DN/20210145739&RS=DN/202
Benzinga · 05/20 15:28
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Benzinga · 05/20 12:14
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11)
Benzinga · 05/12 12:57
H.C. Wainwright Thinks Pulmatrix’s Stock is Going to Recover
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Pulmatrix (PULM), with a price target of $5.00. The company's
SmarterAnalyst · 05/12 10:16
Pulmatrix Q1 EPS $(0.09) Up From $(0.23) YoY, Sales $1.39M Down From $2.76M YoY
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.09) per share. This is a 60.87 percent increase over losses of $(0.23) per share from the same period last year. The company reported $1.39 million in sales this
Benzinga · 05/11 20:54
10-Q: PULMATRIX, INC.
(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. The information set forth below...
Edgar Online - (EDG = 10Q, 10K) · 05/11 20:49
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PULM. Analyze the recent business situations of Pulmatrix through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PULM stock price target is 5.00 with a high estimate of 5.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 37
Institutional Holdings: 7.07M
% Owned: 12.57%
Shares Outstanding: 56.25M
TypeInstitutionsShares
Increased
10
1.85M
New
5
197.22K
Decreased
5
403.35K
Sold Out
4
2.72M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.29%
Pharmaceuticals & Medical Research
-0.72%
Key Executives
Chairman/Independent Director
Michael Higgins
Chief Executive Officer/Director
Ted Raad
President/Chief Executive Officer/Director
Teofilo Raad
Vice President - Finance
Michelle Siegert
Director
Todd Bazemore
Director
Christopher Cabell
Independent Director
Rick Batycky
Independent Director
Mark Iwicki
No Data
About PULM
Pulmatrix, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing inhaled therapies to address serious respiratory disease. The Company designs and develops inhaled therapeutic products based on its dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways. iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with a broad range of drug substances including small molecules and biologics. The Company’s therapeutic candidates are Pulmazole, PUR1800, PUR5700, PUR3000 and PUR4000.

Webull offers kinds of Pulmatrix Inc stock information, including NASDAQ:PULM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PULM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PULM stock methods without spending real money on the virtual paper trading platform.